Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining DNA methyltransferase and histone deacetylase inhibition to treat acute myeloid leukemia/myelodysplastic syndrome: achievements and challenges.

× No keyword cloud information.

11 in total

1. Phase I study of AR-42 and decitabine in acute myeloid leukemia.

Authors: Sophia G Liva; Christopher C Coss; Jiang Wang; William Blum; Rebecca Klisovic; Bhavana Bhatnagar; Katherine Walsh; Susan Geyer; Qiuhong Zhao; Ramiro Garzon; Guido Marcucci; Mitch A Phelps; Alison R Walker
Journal: Leuk Lymphoma Date: 2020-02-08

2. Knockdown of SALL4 Protein Enhances All-trans Retinoic Acid-induced Cellular Differentiation in Acute Myeloid Leukemia Cells.

Authors: Li Liu; Liang Liu; Lai-Han Leung; Austin J Cooney; Changyi Chen; Todd K Rosengart; Yupo Ma; Jianchang Yang
Journal: J Biol Chem Date: 2015-03-03 Impact factor: 5.157

Review 3. Precision therapy for acute myeloid leukemia.

Authors: Xue Yang; Jianxiang Wang
Journal: J Hematol Oncol Date: 2018-01-05 Impact factor: 17.388

4. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Authors: G Garcia-Manero; M A Sekeres; M Egyed; M Breccia; C Graux; J D Cavenagh; H Salman; A Illes; P Fenaux; D J DeAngelo; R Stauder; K Yee; N Zhu; J-H Lee; D Valcarcel; A MacWhannell; Z Borbenyi; L Gazi; S Acharyya; S Ide; M Marker; O G Ottmann
Journal: Leukemia Date: 2017-05-26 Impact factor: 11.528

5. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.

Authors: Håkon Reikvam; Randi Hovland; Rakel Brendsdal Forthun; Sigrid Erdal; Bjørn Tore Gjertsen; Hanne Fredly; Øystein Bruserud
Journal: BMC Cancer Date: 2017-09-06 Impact factor: 4.430

6. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Authors: Chengyin Min; Nathan Moore; Jeffrey R Shearstone; Steven N Quayle; Pengyu Huang; John H van Duzer; Matthew B Jarpe; Simon S Jones; Min Yang
Journal: PLoS One Date: 2017-01-06 Impact factor: 3.240

Review 7. Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.

Authors: Younguk Sun; Bo-Rui Chen; Aniruddha Deshpande
Journal: Front Oncol Date: 2018-02-23 Impact factor: 6.244

8. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Authors: Yunan Li; Mingying Zhang; Mengyao Sheng; Peng Zhang; Zizhen Chen; Wen Xing; Jie Bai; Tao Cheng; Feng-Chun Yang; Yuan Zhou
Journal: J Cancer Res Clin Oncol Date: 2018-03-28 Impact factor: 4.553

9. Biomodulatory Treatment With Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis.

Authors: Sebastian Klobuch; Tim Steinberg; Emanuele Bruni; Carina Mirbeth; Bernhard Heilmeier; Lina Ghibelli; Wolfgang Herr; Albrecht Reichle; Simone Thomas
Journal: Front Pharmacol Date: 2018-11-27 Impact factor: 5.810

Review 10. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature.

Authors: Andrea Kuendgen; Catharina Müller-Thomas; Michael Lauseker; Torsten Haferlach; Petra Urbaniak; Thomas Schroeder; Carolin Brings; Michael Wulfert; Manja Meggendorfer; Barbara Hildebrandt; Beate Betz; Brigitte Royer-Pokora; Norbert Gattermann; Rainer Haas; Ulrich Germing; Katharina S Götze
Journal: Oncotarget Date: 2018-06-12